The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement

Acta Diabetologica

Volumn 51, Issue 2, 2014, Pages 239-246

  Tornese, Gianluca ^a   Iafusco, Dario ^b   Monasta, Lorenzo ^a   Agnoletto, Chiara ^c   Tisato, Veronica ^c   Ventura, Alessandro ^a,d   Zauli, Giorgio ^a   Secchiero, Paola ^c  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Insulin requirement; Ketoacidosis; TRAIL; Type 1 diabetes mellitus

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INSULIN ANTIBODY; ISOPHANE INSULIN; PANCREAS ISLET CELL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; BLOOD; DIABETES MELLITUS, TYPE 1; KETOACIDOSIS; METABOLISM; NONPARAMETRIC TEST; ONSET AGE;

ADOLESCENT; AGE OF ONSET; AUTOANTIBODIES; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; KETOSIS; MALE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84898458607     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-013-0507-5     Document Type: Article

References (36)

1. Myers M, Zimmet P (2008) Halting the accelerating epidemic of type 1 diabetes. Lancet 371:1730-1731
2. Harjutsalo V, Sjoberg L, Tuomilehto J (2008) Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371:1777-1782
3. Van Belle TL, Coppieters KT, Von Herrath MG (2011) Type 1 diabetes: etiology, immunology and therapeutic strategies. Physiol Rev 91:79-118
4. Domínguez-Bendala J, Ricordi C (2012) Present and future cell therapies for pancreatic beta cell replenishment. World J Gastroenterol 18:6876-6884
5. Hirabara SM, Gorjão R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R (2012) Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol 2012:379024
6. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331-340
7. Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15:42-48
8. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356-1361
9. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32:1341-1350
10. Ikeda T, Hirata S, Fukushima S, Matsunaga Y, Ito T, Uchino M, Nishimura Y, Senju S (2010) Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J Immunol 185:5259-5267
11. Vinay DS, Kwon BS (2011) The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol 164:145-157
12. Martinez-Lostao L, Marzo I, Anel A, Naval J (2012) Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol 83:1475-1483
13. Bernardi S, Norcio A, Toffoli B, Zauli G, Secchiero P (2012) Potential role of TRAIL in the management of autoimmune diabetes mellitus. Curr Pharm Des 18:5759-5765
14. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chen YH (2013) Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52:2274-2278
15. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L, Grattan M, Meagher C, Zucker P, Chen YH, Nagle J, Taub D, Delovitch TL (2003) Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52:1967-1975
16. - mice. Diabetologia 54:3157-3167
17. Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B, Secchiero P (2010) Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 59:1261-1265
18. Kang S, Park EJ, Joe Y, Seo E, Park MK (2010) Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology 151:5638-5646
19. Bangstad HJ, Danne T, Deeb LC, Jarosz-Chobot P, Urakami T, Hanas R, International Society for Pediatric and Adolescent Diabetes (2009) ISPAD Clinical Practice Consensus Guidelines 2009 Compendium Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 10(12):82-99
20. Pozzilli P, Manfrini S, Buzzetti R, Lampeter E, De Leeuw I, Iafusco D, Prisco M, Ionescu-Tirgoviste C, Kolouskova S, Linn T, Ludvigsson J, Madàcsy L, Seremak Mrozikiewicz A, Mrozikiewicz PM, Podar T, Vavrinec J, Vialettes B, Visalli N, Yilmaz T, Browne PD (2005) Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabets Res Clin Pract 68:258-264
21. Betterle C, Presotto F, Magrin L, Pedini B, Moro L, Caretto A, Zanchetta R (1994) The natural history of pre-type 1 (insulin-dependent) diabetes mellitus in patients with autoimmune endocrine diseases. Diabetologia 37:95-103
22. Betterle C, Lazzarotto F, Fusari A, Zanchetta R, Benedini S, Pedini B, Moscon A, Presotto F (2006) Pancreatic autoantibodies in Italian patients with newly diagnosed type 1 diabetes mellitus over the age of 20 years. Acta Diabetol 43:79-83
23. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166:557-563
24. Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, Zauli G (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One 4:e4442
25. Marigliano M, Morandi A, Maschio M, Sabbion A, Contreas G, Tomasselli F, Tommasi M, Maffeis C (2013) Nutritional education and carbohydrate counting in children with type 1 diabetes treated with continuous subcutaneous insulin infusion: the effects on dietary habits, body composition and glycometabolic control. Acta Diabetol Jun 19 [Epub ahead of print]
26. Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, TrialNet Natural History Committee, Type 1 Diabetes TrialNet Study Group (2009) The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes 10:97-104
27. Uçar A, Saka N, Baş F, Sukur M, Poyrazoǧlu S, Darendeliler F, Bundak R (2013) Frequency and severity of ketoacidosis at onset of autoimmune type 1 diabetes over the past decade in children referred to a tertiary paediatric care centre: potential impact of a national programme highlighted. J Pediatr Endocrinol Metab 8:1-7. doi: 10.1515/jpem-2013-0060 [Epub ahead of print]
28. Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, Cooper ME, Thomas MC (2012) TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 123:547-555
29. Brombo G, Volpato S, Secchiero P, Passaro A, Bosi C, Zuliani G, Zauli G (2013) Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol. PLoS One 8:e58225
30. Keuper M, Wernstedt Asterholm I, Scherer PE, Westhoff MA, Möller P, Debatin KM, Strauss G, Wabitsch M, Fischer-Posovszky P (2013) TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma. Cell Death Dis 24(4):e474
31. Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G (2010) Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 211:333-336
32. Maxwell PR, Timms PM, Chandran S, Gordon D (2001) Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18:777-780
33. Xue M, Thompson PJ, Clifton-Bligh R, Fulcher G, Gallery ED, Jackson C (2005) Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type 1 diabetes. Int J Biochem Cell Biol 37:2406-2416
34. Han X, Sun Y, Scott S, Bleich D (2001) Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells. Diabetes 50:1047-1055
35. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839-2846
36. Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM (2011) Evaluation of pharmacodynamic biomarkers in a phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer 105:1830-1838